Administrative Core

项目总结/摘要： 2019冠状病毒病加剧了对下一次健康危机毫无准备的可怕后果。一个迫在眉睫的危机 涉及抗生素耐药性细菌感染的阴险上升，需要进行我们的研究中描述的研究。 U19申请，题为“抗击抗药性感染的创新战略”， RFA-AI-20-001（对抗抗生素耐药细菌跨学科研究单位（CARBIRU））。 我们的建议被用来将基础科学转化为新型的抗肿瘤药物， 在美国的感染以及常见的医院获得性感染。此U19应用程序使用 多部门，多机构，跨学科的高度积极的微生物学，细胞， 生物学/生理学、免疫学和药物化学研究人员开发 能够：i）治疗常见感染;和/或ii）增加敏感性的治疗剂和化合物 现有的抗生素库。行政核心（AC）将负责协调 活动和监测三个研究项目和两个科学核心的进展，以实现 U19计划的总体目标。为了实现这一目标，AC领导人在执行官的帮助下， 委员会由研究项目和核心的领导人组成，将监督和协调 通过以下方式促进项目和核心成员的活动：i）促进频繁的互动; ii）支持 数据、方法和想法的交流; iii）促进与机构和外部专家的互动， 获得建议，以更好地发挥整个计划的作用，并将计划的结果转化为 治疗开发;以及iv）协调向授予机构报告的财务和科学进展 工作人员此外，AC将协调积极参与U19，以确保其整体成功。

PROJECT SUMMARY/ ABSTRACT: COVID-19 exemplifies the dire consequences of being unprepared for the next health crisis. One looming crisis involves the insidious rise of antibiotic resistant bacterial infections, necessitating the research described in our U19 application entitled “Innovative strategies to combat antibiotic-resistant infections” in response to RFA-AI-20-001 (Combating Antibiotic-resistant Bacteria Interdisciplinary Research Units (CARBIRU)). Our proposal is leveraged to translate basic science into new types of antibiotic-sparing medicines for common infections in the United States as well as common hospital-acquired infections. This U19 application utilizes a multi-departmental, multi-institutional, and interdisciplinary group of highly motivated microbiology, cell biology/physiology, immunology and medicinal chemistry researchers to develop antibiotic-sparing therapeutics and compounds that are capable of: i) treating common infections; and/or ii) increasing sensitivity to the current arsenal of available antibiotics. The Administrative Core (AC) will be responsible for coordinating the activities and monitoring the progress of the three research projects and the two scientific cores to achieve the overall goals of the U19 program. To accomplish this, the AC Leader, with the help of an Executive Committee comprising of the Leaders of the Research Projects and Cores, will oversee and coordinate the activities of the members of the Projects and Cores by: i) fostering frequent interactions; ii) supporting the exchange of data, methodologies, and ideas; iii) facilitating interactions with institutional and outside experts to gain advice for better functioning of the overall program and for translation of the program's findings into therapeutics development; and iv) coordinating financial and scientific progress reporting to granting agency staff. In addition, the AC will coordinate active participation in the U19 to ensure its overall success.